Deal Details

Xenon Completes $747.5 Million Follow-On Offering

Healthcare

Xenon follow-on offering

Summary

Xenon Pharmaceuticals Inc. (“Xenon”) (NASDAQ: XENE) recently completed the pricing of an upsized underwritten public offering (the “Offering”) of 12,236,843 shares of its common stock, including 1,710,526 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price of $57.00 per share and 877,194 pre-funded warrants at a price of $56.9999 per pre-funded warrant, generating gross proceeds of approximately $747.5 million.

Baird served as lead manager on this Offering.

About

Xenon is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent Kᵥ7 potassium channel opener in Phase III clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kᵥ7 and Naᵥ1.7 programs in Phase I development for the potential treatment of pain. Xenon is headquartered in Burnaby, British Columbia.